Stopping a medicine is a prescribing decision and carries the same burden of proof as starting one. That sentence is the whole of this stage. You will be asked to reduce a long medication list for an older adult, to justify each removal from evidence rather than from a feeling that the list is too long, and to monitor the stop with the same care a start would receive. The tools that flag potentially inappropriate medicines are screens rather than verdicts, and doctoral writing is expected to treat them that way. What your section collects, a discussion contribution or an uploaded case or both, is set by your syllabus alone.
Our sequence, our responsibility. Walden does not post syllabi where the public can read them and the course guide requires a login, so the position of any deliverable is something only your classroom can confirm, and we have arranged these manuals to build on one another rather than to reproduce an order we cannot see. The schedule in your section governs.
How a deprescribing paper is marked
The row that carries most weight asks what the patient is trying to achieve. An 84 year old prioritizing independence and freedom from dizziness is a different problem from one prioritizing the longest possible survival, and the medication decisions follow from that conversation rather than from a screening list.
A second row tests how you used the explicit criteria. Published lists of medicines to avoid in older adults are designed as prompts for review, and quoting one as though it forbade a drug outright misreads the tool and loses the row grading judgment.
The third row grades what happens after the stop. Rebound, withdrawal and the return of the original symptom are predictable events, and a paper that stops five drugs and monitors none of the consequences has not finished the clinical reasoning.
Six moves through a medication reduction
Six stages our bench uses once a case asks which medicines should come off a list.
-
Start from what the person wants the medicines to do
Ask what matters to this patient over the next few years, and record the answer in their words. Every subsequent judgment about benefit rests on that statement, and a paper that skips it is guessing at the goal.
-
Treat screening tools as prompts for thought
Explicit criteria surface candidates for review. Use them to generate questions, then answer each one with reasoning about this patient, because the tool identifies a risk and only you can weigh it.
-
Add up the anticholinergic load across the whole list
Several individually mild agents together produce confusion, retention, falls and dry mouth. Score the cumulative burden, name the contributors, and treat the total rather than arguing about any single tablet.
-
Trace the newest symptom back to the newest drug
A symptom that appeared shortly after a medicine started is a hypothesis worth testing before another prescription is written to treat it. Set out the timeline and let the sequence carry the argument.
-
State what the evidence for stopping actually shows
Some withdrawals have trial support and some have only expert opinion, and the honest position differs between them. Say which kind of evidence stands behind each removal you propose.
-
Follow the stop as closely as you would a start
Give each discontinuation a taper where one is needed, a monitoring interval, an expected course, and a restart criterion. A stop without follow up is an experiment nobody is watching.
The shape of a deprescribing case
A working outline from our bench, not an institutional form, and your posted rubric should decide where the weight sits.
| Section | What the section holds | What the row rewards |
|---|---|---|
| Patient priorities | What the person wants, what they fear, and the horizon they are planning over. | Priorities in the patient's own words, used later to justify decisions. |
| The list as it stands | Every medicine including those bought without a prescription, with start dates where known. | A complete list with durations, since duration often reveals the forgotten drug. |
| Risk accumulation | Anticholinergic load, sedative load, and overlapping mechanisms across the list. | Cumulative burden quantified rather than described drug by drug. |
| Candidates for removal | Which agents come off, in what order, and the reasoning for each. | One clear justification per drug, ranked so the riskiest goes first. |
| Evidence quality | What supports each stop, from trial data to consensus opinion. | Honest labeling of where evidence is strong and where it is thin. |
| Withdrawal plan | Tapers, monitoring intervals, expected symptoms and restart criteria. | A follow up design that treats stopping with the seriousness of starting. |
Annotated sample excerpt: after a fall
This passage shows cumulative burden used as the argument, with the evidence for each stop labeled honestly.
Three agents on this list contribute anticholinergic activity and two more contribute sedation, so the fall that brought her to the clinic is better explained by accumulated burden than by any single prescription, and the review therefore targets the total rather than debating each tablet in isolation.1 The sedative hypnotic is addressed first because randomised work on direct patient education has achieved discontinuation in roughly one in four long term users, which is a stronger evidence base than exists for most other withdrawals being proposed here.2 Reduction proceeds at one quarter of the dose every two weeks with rebound insomnia described to her in advance as expected and temporary, a review call at two weeks, and a written criterion for pausing if daytime function worsens rather than improves.3
- 1Cumulative burden replaces the usual drug by drug argument, which is the reasoning move that a falls case is actually testing.
- 2The evidence behind this particular stop is named and ranked against the others, showing appraisal instead of a blanket claim that less is better.
- 3The expected withdrawal effect is disclosed before it happens and paired with a pause rule, so the taper cannot be abandoned at the first bad night.
Send the medication list your section supplied plus whatever rubric came attached, and the first premium sample costs nothing, burden analysis and withdrawal monitoring written out in full.
Five errors in a deprescribing paper
- Fewer drugs treated as an end in itself. Reduction is a means to a goal the patient named, and a paper that never states the goal cannot show the removal served it.
- A screening list quoted as prohibition. Explicit criteria flag medicines for review rather than banning them, and reading them as rules loses the judgment row.
- Everything stopped at once. Simultaneous withdrawals make it impossible to attribute any change, and the paper forfeits the ability to interpret its own plan.
- Withdrawal effects left undescribed. Rebound and discontinuation symptoms are foreseeable, and a patient warned in advance is far more likely to complete the reduction.
- No criterion for restarting. Some stops fail, and a plan that cannot recognize its own failure is not a clinical plan.
Check the review before you submit
- Patient priorities are recorded before any drug is removed
- The full list includes non-prescription and as-needed items
- Cumulative anticholinergic and sedative burden is quantified
- Removals are ordered, with the highest risk agent addressed first
- The evidence behind each stop is described by its strength
- Each discontinuation carries monitoring and a restart criterion
Medication reduction case due?
Send the list, the patient background and the classroom grading grid. In 24 to 48 hours a premium original reaches you with cumulative burden calculated, every stop justified by named evidence and a withdrawal plan attached, rewritten free of charge until it scores.